Utilization and Clinical Benefit of Immune Checkpoint Inhibitor in Veterans With Microsatellite Instability-High Prostate CancerSeptember 9, 2022Prostate CancerColon and RectalOncology
Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access SettingAugust 11, 2022Colon and RectalOncologyProstate Cancer
Most men with low-risk prostate tumors now forgoing treatmentMay 17, 2022Genitourinary CancerOncologyCancerProstate Cancer
Is it time to remove ‘cancer’ label from low-risk prostate tumors?May 6, 2022Genitourinary CancerOncologyProstate CancerCancer
Cancer Data Trends 2022March 30, 2022CancerBreast CancerGenitourinary CancerLung CancerProstate CancerOncologyHematologic Malignancies
MRI far safer than CT for guiding radiotherapy in prostate cancerFebruary 24, 2022Genitourinary CancerOncologyProstate CancerCancer
Unfavorable intermediate-risk prostate cancer: EBRT plus BT improve survivalFebruary 15, 2022Prostate Cancer
Intermediate-/high-risk prostate cancer: Focal HIFU provides good controlFebruary 15, 2022Prostate Cancer
Prostate cancer: ACEi use during radiotherapy may protect against hematuriaFebruary 15, 2022Prostate Cancer
Obesity is linked to high-risk prostate cancer in multiethnic populationFebruary 15, 2022Prostate Cancer
Prostate cancer: Active surveillance may be appropriate in selected intermediate-risk patientsFebruary 15, 2022Prostate Cancer
Prostate cancer: Salvage radiotherapy after surgery extends long-term survivalFebruary 15, 2022Prostate Cancer
